Katholieke Universiteit Leuven and Springworks Therapeutics Inc. have jointly identified tetrahydropyridopyrimidines acting as transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) or WW domain-containing transcription regulator protein 1 (WWTR1; TAZ)/TEAD interaction inhibitors.
A Retune Pharma Inc. patent describes new insulin-like growth factor 1 receptor (IGF-1R; CD221) inhibitors reported to be useful for the treatment of cancer, thyroid-associated ophthalmopathy (Graves ophthalmopathy) and autoimmune disease.
Serengen GmbH and Deargen Inc. have established a collaboration to accelerate the drug discovery process by bringing together Serengen’s novel DNA encoded library (DEL) technology with Deargen’s artificial intelligence (AI)-driven drug discovery platform, Deardti.
Researchers from Genentech Inc. presented preclinical data for the novel transient receptor potential ankyrin 1 (TRPA1) antagonist GDC-6599, currently in phase II development for respiratory indications.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines against ‘disease X,’ the threat of unknown pathogens with the potential to cause pandemics.
Human lipoprotein(a) (Lp(a)) is a lipoprotein complex composed of a low-density lipoprotein (LDL) particle and a large highly polymorphic glycoprotein named apolipoprotein (a) (apo(a)). There is evidence that Lp(a) is linked to cardiovascular disorder risk.
CCM Biosciences Inc. has launched with a focus on discovering and developing novel drugs, including small molecules, gene therapies, biologics and nanomedicines, and companion diagnostic tests.
At the recent ESC Congress, researchers from University of Tennessee and Attralus Inc. presented preclinical data on the novel pan-amyloid-binding peptide fusion immunoglobulin AT-02, which is being developed for the treatment of amyloidosis.
Under pathologic conditions such as vascular injury or atherosclerosis, the hyperactivation of platelets may lead to occlusive thrombus formation, myocardial infarction or stroke. Although there are several targets for clot prevention validated clinically, these strategies may present bleeding risk as a limitation. Researchers from the University of Michigan have reported on CS-014, a histone deacetylase (HDAC) inhibitor aimed to reduce clot formation without risk of bleeding.
“Change is the only constant” is an ageless truth. In the search for age-related biomarkers, it is also a prosaic confounding factor. Age-related biomarkers will be critical for the development of antiaging therapeutics. “Nobody is planning to do a life span study in humans,” Eric Verdin told the audience at the 10th Conference on Aging Research and Drug Development in Copenhagen on Monday. “Hence the need for … surrogate markers.” And “we are not there … we are actually quite far from there.”